Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2010

Conditions
Non Small Cell Lung Cancer
Interventions
RADIATION

Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)

one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected

RADIATION

Technetium 99m ethylenedicysteine-deoxyglucose

99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)

RADIATION

18 F fluorodeoxyglucose

single injection of 18F FDG (range 10-20 mCi)

Trial Locations (3)

10461

Montefiore Medical Center, The Bronx

55905

Mayo Clinic, Division of Nuclear Medicine, Rochester

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

Numoda

INDUSTRY

collaborator

Venn Life Sciences

OTHER

collaborator

Camargo Pharmaceutical Services

INDUSTRY

collaborator

Biomedical Systems

INDUSTRY

lead

Cell>Point LLC

INDUSTRY